A tumor cell lysate vaccine administered in combination with anti-CTLA4 at 14 weeks of age failed to reduce prostate weight at 19 weeks of age, but the incidence of tumors (histologic invasive adenocarcinoma) was reduced from 69% in controls to 43% in the treatment group [43]. This evidence concerns the gene CTLA4 and neoplasm.